Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
galvokimig (UCB)
- Development stage
- Phase 1
- Lead developer
- UCB
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
Galvokimig (UCB5285) is a novel multi-specific antibody-based therapeutic developed by UCB Biopharma for the treatment of moderate-to-severe atopic dermatitis. It is designed to simultaneously inhibit interleukin-13 (IL-13), interleukin-17A (IL-17A), and interleukin-17F (IL-17F), thereby selectively targeting both Th2 and Th17 inflammatory pathways that contribute to chronic skin inflammation. The molecule is engineered with an extended half-life through albumin binding, potentially allowing for less frequent dosing. In a Phase 1/2a clinical trial, galvokimig demonstrated significant efficacy, with a median of 64.9% of patients achieving EASI75 at Week 12 compared to 12.3% for placebo. UCB plans to initiate a Phase 2b trial for atopic dermatitis by the end of 2025.
- Other names
- galvokimig
02
Targets
IL17F (Interleukin 17F)IL-17A (Interleukin-17A)IL-13 (Interleukin-13)
Beyond the preview
Go deeper on galvokimig (UCB).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on galvokimig (UCB).